359 related articles for article (PubMed ID: 32754598)
1. The Role of Tyrosine Kinases as a Critical Prognostic Parameter and Its Targeted Therapies in Ewing Sarcoma.
Jin W
Front Cell Dev Biol; 2020; 8():613. PubMed ID: 32754598
[TBL] [Abstract][Full Text] [Related]
2. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK
J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088
[TBL] [Abstract][Full Text] [Related]
3. TrkC, a novel prognostic marker, induces and maintains cell survival and metastatic dissemination of Ewing sarcoma by inhibiting EWSR1-FLI1 degradation.
Kim MS; Lee WS; Lee H; Jin W
Cell Death Dis; 2022 Sep; 13(9):836. PubMed ID: 36171207
[TBL] [Abstract][Full Text] [Related]
4. Potential approaches to the treatment of Ewing's sarcoma.
Yu H; Ge Y; Guo L; Huang L
Oncotarget; 2017 Jan; 8(3):5523-5539. PubMed ID: 27740934
[TBL] [Abstract][Full Text] [Related]
5. Zooming in on Long Non-Coding RNAs in Ewing Sarcoma Pathogenesis.
Aryee DNT; Fock V; Kapoor U; Radic-Sarikas B; Kovar H
Cells; 2022 Apr; 11(8):. PubMed ID: 35455947
[TBL] [Abstract][Full Text] [Related]
6. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
[TBL] [Abstract][Full Text] [Related]
7. Challenges in modeling EWS-FLI1-driven transgenic mouse model for Ewing sarcoma.
Ramachandran B; Rajkumar T; Gopisetty G
Am J Transl Res; 2021; 13(11):12181-12194. PubMed ID: 34956445
[TBL] [Abstract][Full Text] [Related]
8. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.
Robin TP; Smith A; McKinsey E; Reaves L; Jedlicka P; Ford HL
Mol Cancer Res; 2012 Aug; 10(8):1098-108. PubMed ID: 22723308
[TBL] [Abstract][Full Text] [Related]
9. Slit2 signaling stimulates Ewing sarcoma growth.
Suvarna K; Jayabal P; Ma X; Shiio Y
Genes Cancer; 2022; 13():88-99. PubMed ID: 36533189
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC
Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769
[TBL] [Abstract][Full Text] [Related]
11. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
12. Cell cycle arrest and apoptosis are early events in radiosensitization of EWS::FLI1
Lin MY; Damron TA; Horton JA
Int J Radiat Biol; 2023; 99(10):1570-1583. PubMed ID: 36913323
[TBL] [Abstract][Full Text] [Related]
13. IRE1α-XBP1 inhibitors exerted anti-tumor activities in Ewing's sarcoma.
Tanabe Y; Suehara Y; Kohsaka S; Hayashi T; Akaike K; Mukaihara K; Kurihara T; Kim Y; Okubo T; Ishii M; Kazuno S; Kaneko K; Saito T
Oncotarget; 2018 Mar; 9(18):14428-14443. PubMed ID: 29581854
[TBL] [Abstract][Full Text] [Related]
14. Ewing sarcoma from molecular biology to the clinic.
Dupuy M; Lamoureux F; Mullard M; Postec A; Regnier L; Baud'huin M; Georges S; Brounais-Le Royer B; Ory B; Rédini F; Verrecchia F
Front Cell Dev Biol; 2023; 11():1248753. PubMed ID: 37752913
[TBL] [Abstract][Full Text] [Related]
15. Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?
Lawlor ER; Sorensen PH
Crit Rev Oncog; 2015; 20(3-4):155-71. PubMed ID: 26349414
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G
Zöllner SK; Selvanathan SP; Graham GT; Commins RMT; Hong SH; Moseley E; Parks S; Haladyna JN; Erkizan HV; Dirksen U; Hogarty MD; Üren A; Toretsky JA
Sci Signal; 2017 Oct; 10(499):. PubMed ID: 28974650
[TBL] [Abstract][Full Text] [Related]
17. Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival.
Tilan JU; Krailo M; Barkauskas DA; Galli S; Mtaweh H; Long J; Wang H; Hawkins K; Lu C; Jeha D; Izycka-Swieszewska E; Lawlor ER; Toretsky JA; Kitlinska JB
Cancer; 2015 Mar; 121(5):697-707. PubMed ID: 25387699
[TBL] [Abstract][Full Text] [Related]
18. KDM5A and PHF2 positively control expression of pro-metastatic genes repressed by EWS/Fli1, and promote growth and metastatic properties in Ewing sarcoma.
McCann TS; Parrish JK; Hsieh J; Sechler M; Sobral LM; Self C; Jones KL; Goodspeed A; Costello JC; Jedlicka P
Oncotarget; 2020 Oct; 11(43):3818-3831. PubMed ID: 33196691
[TBL] [Abstract][Full Text] [Related]
19. EWS/FLI1 Characterization, Activation, Repression, Target Genes and Therapeutic Opportunities in Ewing Sarcoma.
Yasir M; Park J; Chun W
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894854
[TBL] [Abstract][Full Text] [Related]
20. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
